Latest KFF Health News Stories
California Governor’s Big Promises on Drug Prices Are Slow to Materialize
Gov. Gavin Newsom has launched several initiatives to cut rising drug prices, but the savings haven’t been as monumental as he promised. And his plan to have California make its own generic drugs hasn’t gotten off the ground.
Changes to Medi-Cal’s Troubled Drug Program Reduce Backlog in California, but Problems Persist
After a troubled start to the new Medi-Cal prescription drug program, the state’s contractor has hired staffers to reduce wait times for medication approvals and patients seeking help. But some doctors and clinics report that patients continue to face delays.
Journalists Review Hospital Penalties and Problems Riddling Medicaid Rx Program
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
‘Somebody Is Gonna Die’: Medi-Cal Patients Struggle to Fill Prescriptions
Problems with California’s new Medicaid prescription drug program are preventing thousands of patients from getting their medications, including some life-saving ones. State officials say they’re working on fixes.
I Write About America’s Absurd Health Care System. Then I Got Caught Up in It.
A KHN reporter had written for years about the people left behind by the absurdly complex and expensive U.S. health care system. Then he found himself navigating that maze as he tried to get his insulin prescription filled.
KHN’s ‘What the Health?’: Dealing With Drug Prices
Medicare officials tentatively plan to restrict the use of a controversial Alzheimer’s drug to only those patients participating in clinical trials, while the Department of Health and Human Services looks into lowering the monthly Medicare Part B premium. Meanwhile, covid confusion still reigns, as the Biden administration moves, belatedly, to make more masks and tests available. Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.
Clinics Say State’s New Medicaid Drug Program Will Force Them to Cut Services
On Jan. 1, California started buying prescription drugs for its nearly 14 million Medicaid enrollees, a responsibility that had primarily been held by managed-care insurance plans. State officials estimate California will save hundreds of millions of dollars by flexing its purchasing power, but some health clinics expect to lose money.
KHN’s ‘What the Health?’: Manchin Blows Up Biden’s ‘Build Back Better’
Sen. Joe Manchin (D-W.Va.) dealt a blow to congressional efforts to pass President Joe Biden’s domestic agenda bill, forcing Democrats to regroup starting in 2022. Meanwhile, the omicron covid variant spreads rapidly in the U.S., threatening the stability of the nation’s health care system. Joanne Kenen of Politico and the Johns Hopkins School of Public Health, Rachel Cohrs of Stat and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more, plus a look back at the year in health policy. Also this week, Rovner interviews Ceci Connolly, president and CEO of the Alliance of Community Health Plans.
Local Pharmacists Fill Rx Void as Big Brands Pull Out of Rural Areas
Stores like Walmart and Shopko opened pharmacies in small towns, either buying out the local pharmacy or driving it out of business. What happens when those chains later withdraw, leaving communities with no pharmacy?
Con más muertes por sobredosis, defensores claman por una naloxona de venta libre
La administración Biden ha destinado $30 millones a programas de reducción de daños por adicciones. Pero defensores dicen que la principal barrera es que la naloxona sigue siendo de venta bajo receta.
With Overdose Deaths Surging, Advocates on the Ground Push for Over-the-Counter Naloxone
Harm-reduction groups say that requiring a doctor to sign off on their orders of the overdose reversal drug is one of the biggest barriers they face in obtaining the lifesaving medication.
Texas Toughens Ban on Medication-by-Mail Abortions With Jail Time and Hefty Fine
Last week, on the same day the Supreme Court heard a case that could overturn Roe v. Wade, the landmark ruling on abortion rights, Texas enacted a law that creates criminal penalties for anyone who prescribes medication abortions via telehealth or mail.
Journalists Explore Health Care Disparities and Policy Pitfalls
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
Success of Covid Antiviral Pills Hinges on Access to Speedy and Accurate Tests
The promising antiviral drugs to treat covid can halt hospitalizations and deaths, but only if they’re given to patients within three to five days of their first symptoms, a narrow window many people won’t meet. Here’s why.
Public Opinion Is Unified on Lowering Drug Prices. Why Are Leaders Settling for Less?
Politicians and many health experts have done their best to see the glass half-full in the plan put forward by congressional Democrats and the president. But it’s “a far cry” from what other nations do to rein in drug prices, and polls show most voters demand more protection.
Cómo las comunidades rurales están perdiendo sus farmacias
Las farmacias de las esquinas, que alguna vez estuvieron tanto en las grandes ciudades como en los pueblos rurales, están desapareciendo de muchas áreas del país, dejando a unos 41 millones de estadounidenses en lo que se conoce como “desiertos de farmacias”, sin fácil acceso a las farmacias.
How Rural Communities Are Losing Their Pharmacies
More than 1,000 independent rural pharmacies have closed since 2003, leaving 630 communities with no retail drugstore. As 41 million people stuck in pharmacy deserts make do, the remaining drugstores struggle to survive.
As Overdose Deaths Soar, DEA-Wary Pharmacies Shy From Dispensing Addiction Medication
A West Virginia pharmacy cleared a Drug Enforcement Administration investigation. But it shut down anyway, highlighting how the agency’s policies reduce the availability of buprenorphine, an important tool for recovery from opioid addiction.
La nueva legislación bajaría dramáticamente el precio de la insulina, y lograría que el impacto de los precios astronómicos no recaigan en el consumidor.
Despite Restraints, Democrats’ Drug Pricing Plan Could Still Aid Consumers
A last-minute agreement among lawmakers restored a provision seeking to hold down rising costs of prescription medicines. Although details on which drugs will be targeted remain sketchy, the legislation would help patients buying insulin and cap Medicare beneficiaries’ out-of-pocket drug costs at $2,000 a year.
